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Antenatal stimulation of lung growth is a reasonable approach to treat congenital 
diaphragmatic hernia (CDH), a disease characterized by pulmonary hypoplasia and 
hypertension. Several evidences from the literature demonstrated a possible 
involvement of renin-angiotensin system (RAS) during fetal lung development. Thus, 
the expression pattern of renin, angiotensin-converting enzyme, angiotensinogen, type 1 
(AT1) and type 2 (AT2) receptors of angiotensin II (ANGII) was assessed by 
immunohistochemistry throughout gestation, whereas the function of RAS in the fetal 
lung was evaluated using fetal rat lung explants. These were morphometrically analyzed 
and intracellular pathway alterations assessed by Western blot. In nitrofen-induced 
CDH model, pregnant rats were treated with saline or PD-123319. In pups, lung growth, 
protein/DNA ratio, radial saccular count, epithelial differentiation and lung maturation, 
vascular morphometry, right ventricular hypertrophy and overload molecular markers, 
gasometry and survival time were evaluated. Results demonstrated that all RAS 
components were constitutively expressed in the lung during gestation and that ANGII 
had a stimulatory effect on lung branching, mediated by AT1 receptor, through p44/42 
and Akt phosphorylation. This stimulatory effect on lung growth was mimicked by 
AT2-antagonist (PD-123319) treatment. In vivo antenatal PD-123319 treatment 
increased lung growth, ameliorated indirect parameters of pulmonary hypertension, 
improved lung function and survival time in non-ventilated CDH pups, without 
maternal or fetal deleterious effects. Therefore, this study demonstrated a local and 
physiologically active RAS during lung morphogenesis. Moreover, selective inhibition 





















 Congenital diaphragmatic hernia (CDH) is a severe developmental anomaly, 
with a mean incidence of 1:2.500 live births, which etiology remains poorly understood 
(1, 2). This congenital anomaly is characterized by a diaphragmatic defect that allows 
intra-thoracic herniation of abdominal organs and consequently maldevelopment of the 
alveoli and pulmonary vessels. For many years, this malformation was thought to be a 
surgical emergence, solely related to a diaphragmatic defect, and potentially curable by 
surgical closure of this defect after birth, which allowed lung expansion. However, 
during 90th years, CDH pathophysiology progressed for a physiological emergence (3, 
4). It is now clear that lung hypoplasia and consecutive persistent pulmonary 
hypertension (PH) associated with this disorder are the key determinants of mortality 
(1-4). Despite the improvements in understanding  CDH pathophysiology and advances 
in neonatal care, such as the use of extra corporeal membrane oxygenation and inhaled 
nitric oxide, the mortality (50%) and morbidity rate in CDH newborns remains 
exceedingly high (1-4). In humans CDH can be accurately diagnosed at second 
trimester during routine ultrasound examination, therefore it is amenable to antenatal 
therapies. Hence, antenatal therapies that promote fetal lung growth remain an 
appealing approach to improve survival of CDH fetuses. However, fetal surgical 
interventions, such as fetal tracheal occlusion, are invasive, technically demanding, 
limited by the maternal and fetal risks, and its efficacy is still not determined, with 
controversial results in survival and morbidity rates (5, 6). Therefore, less invasive 
approaches such as antenatal pharmacological treatment to stimulate lung growth before 
birth and to treat PH are also under investigation (3, 7-10). 
 The renin–angiotensin system (RAS) is a classical endocrine system regulating 




















namely angiotensinogen  (the hepatic derived precursor), two critical enzymes, renin 
(secreted from the juxtaglomerular apparatus of the kidney) and angiotensin-converting 
enzyme (ACE, pulmonary-bound metalloproteinase), whose sequential actions produce 
angiotensin I and the physiologically active, angiotensin II (ANGII), respectively (11).  
ANGII operates on two G protein-coupled receptors, the ANGII type 1 (AT1) and type 2 
(AT2) receptors (11). During the last two decades, additionally to this classic endocrine 
system, evidences have demonstrated the presence of a local RAS with 
autocrine/paracrine actions in several developing organs, such as fetal kidney, heart, 
vasculature and adrenal development (12). 
Regarding lung morphogenesis, there is some evidence that lung expresses ACE 
as well as AT1 and AT2 receptors during fetal development (13-15). However, RAS 
components expression pattern as well as its effects during lung morphogenesis is 
largely unknown. 
In this study, we assessed the expression pattern and function of RAS during 
fetal lung development. Moreover, we assessed the role of RAS as a putative target for 




















MATERIALS AND METHODS 
Animal experiments were performed according to the Portuguese law for animal 
welfare (‘Diário da República, Portaria 1005/92’). Animals were housed in an 
accredited mouse house and treated as specified by the recommendations of the Helsinki 
convention and the ‘Guide for the Care and Use of Laboratory Animals’ published by 
the US National Institutes of Health (NIH Publication No.85-23, revised 1996). 
 
Experimental design and animal model  
 In vitro studies were carried out to assess expression and function of RAS in 
fetal lung, whereas in vivo studies were performed to explore RAS as a target to treat 
fetal lung hypoplasia using the nitrofen-induced CDH rat model (16).  
 Sprague-Dawley female rats (225g; Charles-River; Barcelona, Spain) were 
maintained in appropriate cages under controlled conditions and fed with commercial 
solid food. The rats were mated and checked daily for vaginal plug. The day of plugging 
was defined as gestational day 0.5 for time dating purposes. According to the nitrofen-
induced CDH rat model (16), at 9.5 days-post conception (dpc) randomly selected 
pregnant rats were exposed to 100 mg of nitrofen (2,4-dichlorophenyl-p-
nitrophenylether). At different time-points, fetuses were harvested by caesarean section. 
After fetal decapitation, a toraco-laparotomy was performed under a binocular surgical 
microscope (Leica, Wild M651.MSD, Heerbrugg, Switzerland) to inspect the 
diaphragm and harvest the organs. Fetuses were assigned to three experimental groups: 
i) Control group (C), fetuses not exposed to nitrofen; ii) Nitrofen group (N), fetuses 






















In vitro studies 
 Normal fetuses removed by caesarean section at 13.5, 15.5, 17.5, 19.5 and 21.5 
dpc were sacrificed by decapitation, and lungs dissected and processed for 
immunohistochemistry (IHC). Lungs of fetuses with 13.5 dpc were also dissected to 




IHC was performed on formalin-fixed and paraffin-embedded lungs, as 
previously described by Nogueira-Silva et al (7). Renin antibody (sc-27320; Santa Cruz 
Biotechnology Inc., Santa Cruz, CA, USA) was used in a 1:25 dilution, ACE antibody 
(sc-20791; Santa Cruz Biotechnology Inc.) in a 1:75 dilution, angiotensinogen antibody 
(Abbiotec LLC, San Diego, CA, USA) in a 1:100 dilution, AT1 receptor antibody (sc-
1173; Santa Cruz Biotechnology Inc.) in a 1:50 dilution and AT2 receptor antibody (sc-
9040; Santa Cruz Biotechnology Inc.) in a 1:25 dilution. Incubation with the 
UltraVision detection system anti-polyvalent horseradish peroxidase (Lab Vision 
Corporation, Fremont, CA, USA) or with the goat ImmunoCruz™ Staining System 
(Santa Cruz Biotechnology Inc.) was carried out according to the manufacturer’s 
instructions. 
 
Fetal lung explant cultures 
 Recombinant ANGII (Sigma, St Louis, MO, USA), AT1-antagonist (ZD-7155; 
Tocris Cookson Ltd, Bristol, UK) and AT2-antagonist (PD-123319; kindly supplied by 
Pfizer Inc., Groton, CT, USA) were added daily to lung explants in order to achieve 




















10-5 M. These doses were selected according to the literature (17, 18). This set of 
experiments created the following groups: control (n= 30), ANGII 10-9 (n=10), ANGII 
10-8 (n=11), ANGII 10-7 (n=11), ANGII 10-6 (n=12), ANGII 10-5 (n=12), ANGII 10-4 
(n=12), ZD-7155 (n=12) and PD-123319 (n=15). Furthermore, explants were treated 
with ANGII at 10-9 M in the presence of ZD-7155 or PD-123319 at 10-5 M, creating the 
additional groups: ANG 10-9 + ZD-7155 (n= 12) and ANG 10-9 + PD-123319 (n= 15). 
Cultures were photographed daily and branching morphogenesis was assessed 
according to Nogueira-Silva et al (19). 
 
Western blot analysis 
 After 4 days in culture, lung explants treated with ANGII at 10-9 M, ZD-7155 or 
PD-123319 were processed for western blot analysis of non-phosporylated and 
phosporylated forms of Mitogen-activated protein kinases (MAPKs)[p44/42, p38, JNK 
(MAbs; Cell Signaling Technology Inc., Danvers, MA, USA)] and 
Phosphatidylinositol-3-kinase (PI3K/Akt) (Cell Signaling Technology Inc.) according 
to Nogueira-Silva et al (19). For loading control, blots were probed with β-tubulin MAb 
(Abcam plc, Cambridge, UK) (n=3). Quantitative analysis was performed with Quantity 
One 4.6.5 1-D Analysis Software (Bio-Rad Laboratories Ltd, Hercules, CA, USA). 
In vivo studies 
 Pregnant rats, control or exposed to nitrofen, were anesthetized at 12.5 dpc with 
a mix of ketamine (75mg/Kg) and medetomidine (0.5 mg/Kg) for subcutaneous 
implantation of an osmotic micro-pump filled either with saline or PD-123319  
(randomly), on mid scapular region (Alzet osmotic pump Model 2ML1; Durect 
Corporation, Cupertino, CA, USA). Saline or PD-123319 solution was infused with a 




















atipamezole (0.25 mg/kg) was used and butorfanole (1mg/kg) was administered 
immediately after the surgery. Fetuses were assigned to six experimental groups: 
Control rats treated with saline (C+S); Control rats treated with PD-123319 (C+PD); 
Nitrofen rats treated with saline (N+S); Nitrofen rats treated with PD-123319 (N+PD); 
CDH rats treated with saline (CDH+S); and CDH rats treated with PD-123319 
(CDH+PD).  
 Pregnant rats were randomly assigned for caesarean section at 21.5 dpc or for 
spontaneous delivery at term. 
 The pregnant rats sacrificed at 21.5 dpc were laparotomized and, after 
longitudinal hysterotomy, each fetus (C+S n=14; C+PD n=15; N+S n=15; N+PD n=12; 
CDH+S n=15; CDH+PD n=24) was extracted, weighed and decapitated for organ 
harvesting (lungs, heart and kidneys). Organs were also weighed independently, organs-
to-body weight ratios were assessed and lungs were either snap frozen in liquid nitrogen 
for biochemical analyses or fixed in 4% paraformaldehyde (PAF) for histological 
analyses. In this set of experiments, the level of lung hypoplasia was calculated 
according to Baptista et al (9).  
 
 The pups allowed to be delivered spontaneously at term were placed 
immediately after birth in a light heated box and randomly sacrificed 5 minutes after 
birth or allowed to survive, without any care, support strategies or ventilatory support. 
Those sacrificed by decapitation at minute 5 (C+S n=15; C+PD n=9; N+S n=11; N+PD 
n=6; CDH+S n=12; CDH+PD n=14) were used for blood collection (neck bleeding) and 
gasometric evaluation (i-Stat1 analyser; Abbott, Chicago, Il, USA). These were then 
dissected for identification of CDH. Moreover, hearts were dissected for right 




















were harvested and processed for q-PCR studies. The remaining fetuses were allowed to 
survive (C+S n=10; C+PD n=9; N+S n=14; N+PD n=21; CDH+S n=14; CDH+PD 
n=28), evaluated by two independent – blind observers (M. J. Baptista and S. Nunes) 
and scored at 1, 3, 5 and subsequently at each 5 minutes, using an APGAR-like score 
[Table 1, adapted from Dauger et al (20)]. The moment of death was registered and 
defined by the moment in which the 2 observers attributed an APGAR 0 (marked 
cyanosis, apnea, no spontaneous movements, no response to stimulus). All experiments 
were recorded in video in order to clarify any doubt. These pups were opened post-
mortem for diaphragm inspection. 
 Lungs, heart and kidneys from all pregnant rats were weighed for maternal 
organ-to-body weight ratio analysis. 
 
Biochemical studies for protein/DNA ratio assessment 
 Total lungs (left and right) were processed to determine protein and DNA 
contents. Protein content was assessed by Bradford method (21). DNA was extracted 
using the DNeasy Blood & Tissue Kit (Qiagen, Hilden, Germany).  
 
Histological studies 
 The trachea was cannulated and the lungs were fixed with PAF under a constant 
pressure of 20 cmH2O. Lungs were embedded in paraffin and 4-μm sections were used 
to determine radial saccular count [RSC; using hematoxilin-eosin stain (H&E)], 
epithelial differentiation [IHC for clara cell secretory protein (CCSP) and pro-surfactant 
protein C (SP-C) and determination of glycogen-content using periodic acid-Schiff stain 




















 RSC was estimated according to Emery and Mithal adapted method (22), at 
100x magnification (Olympus BX61 microscope; Olympus, Tokyo, Japan), in 5 animals 
per group, 6 slides per animal (200 μm apart each other), and 10 segments per slide, by 
a blinded examiner (E. Carvalho-Dias). 
 Regarding epithelial differentiation, IHC was performed as previously described 
by Nogueira-Silva et al (7), briefly described above. CCSP antibody [07-623; Upstate 
(Millipore), Billerica, MA, USA] was used in a 1:800 dilution and SP-C antibody 
(AB3428; Chemicon International Inc., Temecula, CA, USA) in a 1:400 dilution. These 
slides and PAS stained slides were observed and photographed (Olympus BX61 
microscope). The percentage of CCSP, SP-C and PAS stained cells per microscopic 
field was scored in a single-blinded fashion (100x and 400x magnification, respectively) 
in 6 independent peripheral and 4 central areas per section (6 slides per animal, 200 μm 
apart each other, and 5 animals per each experimental group). Scoring was as follows: 
1, 0–20% cells/field; 2, 20–40% cells/field; 3, 40–60% cells/field; 4, 60–80% 
cells/field; 5, 80–100%.  
 Weigert’s resorcin fuchsin solution stains elastic fibbers and it was used for 
morphometric assessment of pulmonary arteries (23). Pulmonary arteries were 
distinguished from pulmonary veins on the basis of the structure and position. Arteries 
that were approximately round [i.e., the longest external diameter (ED, distance 
between the external elastic laminae), did not exceed the minimal ED by more than 
50%] and had both clearly visible external and internal elastic laminae were analyzed. 
As the structural changes and pharmacological effects on pulmonary arteries might be 
vessel size dependent, we selected for further analysis arteries subcategorized into 3 
sizes: ED less than 30 μm, ED 30 μm to 50 μm, and ED greater than 50 μm. Then, 




















by internal elastic lamina), external area (EA, defined by external elastic lamina) and 
total area (TA, defined by edge of the vascular sheath) were measured. The percentage 
of medial (MA) and adventitial arterial area (AA) were calculated according to the 
following formulas: MA (%) = [(EA-IA)/EA] x 100; AA (%) = [(TA-EA)/EA] x 100. 
At least 10 arteries for each section were evaluated, 6 sections per animal (200 μm apart 
each other), and 3 animals per each experimental group (at 400x magnification). 
 
Right ventricular hypertrophy evaluation 
 Hearts (C+S n=8; CDH+S n=6; CDH+PD n=8) were used for right ventricle 
(RV) and left ventricle (LV) dissection (LV contains septum). RV and LV were 
weighed separately. The ratio RV/LV was determined and used as an index of right 
ventricular hypertrophy. 
 Other hearts (C+S n=7; CDH+S n=6; CDH+PD n=6) were dissected, 
transversally cut and orientated according to short-axis view of the heart, before fixed in 
PAF and embedded in paraffin. Four-μm sections were stained with H&E and 
photographed at 40x magnification (Olympus BX61 microscope). The right ventricular 
wall thickness was determined in the short-axis view of the heart, in the maximum 
distance between the right side of the interventricular septum to the right ventricular 
free wall, using AxionVision Rel. 4.3 (Carl Zeiss) (5 measurements per animal, 20 μm 
apart each other). 
 
q-PCR studies 
 Right ventricular mRNA expression of angiotensinogen, B-type natriuretic 
peptide (BNP) and endothelin-1 (ET-1), genes previously defined as ventricular 






















 Data are presented as mean ± SEM. Statistical analysis was performed using the 
statistical software SigmaStat (version 3.5; Systat Software Inc., Chicago, IL, USA). 
Multiple group comparisons were made by analysis of variance. For morphometric 
explants studies, western blot analysis, biochemical studies, histological studies, right 
ventricular hypertrophy evaluation and q-PCR studies one-way ANOVA on ranks was 
used. Two-way ANOVA on ranks was used for organ-to-body weight ratio analysis and 
gasometric studies. Student-Newman-Keuls test was used for post-test analysis. 





















RAS components expression pattern during fetal lung development 
 The IHC studies revealed that all RAS components, renin, ACE, 
angiotensinogen, AT1 and AT2 receptors, were expressed throughout all studied 
gestational ages in the fetal lung (Figure 1). Renin was expressed in bronchiolar and 
also in alveolar epithelium throughout gestation (Figure 1A) since 13.5 dpc and appears 
to be maximal in the most immature buds (see supplemental Figure 1A-D). Endothelial 
ACE expression started in larger proximal vessels, early in the gestation, and spreads 
distally to involve progressively smaller vessels (Figure 1B). Interestingly, ACE protein 
was also detectable in epithelial cells since 13.5 dpc (see supplemental Figure 1E). 
Regarding angiotensinogen, protein expression was clearly observed in epithelial cells 
since 15.5 dpc (Figure 1C). Mesenchymal tissue also displayed scattered 
angiotensinogen positive cells, first in endothelial cells and in the later gestational ages 
(19.5 and 21.5 dpc) clearly in vascular smooth muscle cells (Figure 1C). AT1 receptor 
protein was first mainly expressed by undifferentiated mesenchyme at 15.5 dpc and, 
throughout the gestation, it was predominantly expressed by vascular smooth muscle 
cells and scattered in the mesenchyme (Figure 1D). AT2 receptor was expressed in 
bronchial epithelial cells and since 19.5 dpc muscle cells of large blood vessels also 
expressed it (Figure 1E). Moreover, the epithelial AT2 expression was also 
demonstrated at 13.5 dpc (see supplemental Figure 1F). 
 
Role of ANGII in fetal lung development 
 The presence of renin, ACE, angiotensinogen and AT1 and AT2 protein on lung 
during fetal development prompted us to evaluate the role of ANGII, the 




















lung explants were treated with increasing concentrations of recombinant ANGII 
(Figure 2A). ANGII significantly increased the number of peripheral airway buds, 
mainly with concentration of 10-9 M, the minimal concentration studied (Figure 2). On 
the other hand, treatment of lung explants with an AT1-antagonist (ZD-7155) 
significantly inhibited, whereas AT2-antagonist (PD-123319) treatment significantly 
enhanced lung branching in a similar way to the dose of ANGII inducing maximal 
effect (Figure 2C). Moreover, the stimulatory effect on lung branching induced by 
ANGII 10-9 M was completely abolish by AT1-antagonist treatment , and the 
simultaneous lung treatment with ANG 10-9 M and PD-123319 did not accomplish 
additional stimulatory effect on explants growth when compared to ANG 10-9 M 
treatment (Figure 2C). Thus, these results demonstrated that ANGII had a stimulatory 
effect on lung branching, mediated by AT1 receptor. Interestingly, this stimulatory 
effect was mimicked by treatment with AT2-antagonist alone. 
 In order to clarify the intracellular signaling pathways that mediate ANGII 
actions on lung growth, lung explants treated with ANGII at 10-9 M (selected due to its 
maximal effect in explant growth), ZD-7155 or PD-123319 were evaluated for MAPK 
and Akt pathways activation (Figure 3A). AT1 receptor blockage induced a significant 
decrease of p-38 and JNK phosphorylation when compared to control explants (Figure 
3B and 3D, respectively). On the other hand, the increase on lung branching, induced by 
ANGII at 10-9 M and AT2 receptor antagonist, significantly stimulated p44/42 and Akt 
phosphorylation (Figure 3C and E, respectively). 
 
In vivo antenatal PD-123319 treatment improves fetal lung growth  
 Left, right and total lung-to-body weight ratio (LW/BW) were analyzed for 




















model , pups of nitrofen treated dams presented left and right lung hypoplasia, which 
was maximal in CDH+S group. Maternal PD-123319 treatment induced significant 
growth of both left and right lungs in control, nitrofen and CDH groups. In fact, 
LW/BW was significantly higher in the control, nitrofen and also CDH rats treated with 
PD-123319 when compared with the respective saline-treated groups (Figure 4A). 
Indeed, PD-123319 treatment stimulated partial recovery of lung hypoplasia in CDH 
neonates, inducing an increase of 11.4% in total lung weight (Figure 4B). Considering 
these results and in order to assess the potential of PD-123319 as a useful treatment for 
severe lung hypoplasia associated with CDH, we pursued our study focused in 
comparing C+S, CDH+S and CDH+PD groups.  
 Biochemical analysis of lung protein and DNA content demonstrated that there 
was no significant difference in the protein/DNA ratio between C+S, CDH+S and 
CDH+PD groups (C+S 0.024±0.005; CDH+S 0.030±0.004; CDH+PD 0.026±0.002).  
 The histological analysis of lung architecture showed that CDH+S lungs 
appeared to have a thickened septal and saccular walls and an increased amount of 
interstitial tissue when compared with C+S. However, CDH+PD had a significantly 
greater development of saccules and airspaces when compared with CDH+S lungs 
(Figure 5A). In fact, RSC of CDH+S pups was significantly lower when compared with 
C+S group (Figure 5B). However, PD-123319 treatment induced a significant increase 
on RSC of CDH pups, i.e. promoted distal lung development (Figure 5B). 
 Regarding epithelial differentiation and lung maturity, CCSP (proximal 
epithelial cell differentiation marker), SP-C (distal epithelial cell differentiation marker) 
and PAS+ glycogen stores (an indirect signal of immaturity) were evaluated (Figure 6). 
No significant differences in score of CCSP (Figure 6A), SP-C (Figure 6B) and PAS-




















 Concerning other organs than lungs, nitrofen treatment (nitrofen and CDH 
groups) induced decrease of heart-to-body weight (HW/BW) and kidney-to-body 
weight (KW/BW) ratios. However, antenatal PD-123319 treatment did not significantly 
change either HW/BW or KW/BW (see supplemental Figure 2).  
 
Antenatal PD-123319 treatment partially reversed arterial structural abnormality 
and decreased molecular markers of PH on CDH model 
 MA percentage was significantly increased in all arteries (independently of its 
size) in CDH+S group when compared with C+S and CDH+PD groups (Figure 7). 
CDH+PD neonates presented a significant decrease in MA percentage when compared 
with CDH+S for all arterial sizes, with maximal effect on smaller arteries. The effect 
was so evident that CDH+PD arteries had no significant difference in MA percentage 
when compared with C+S group (Figure 7B). Regarding adventitial layer, saline or PD-
treated CDH groups presented a significant increase in AA percentage when compared 
with C+S for all arterial sizes (Figure 7C). Thus, PD-123319 treatment induced 
decrease of MA percentage and did not induce any change on AA percentage.  
 Regarding right ventricular hypertrophy index and right ventricle thickness, 
markers of right ventricular hypertrophy secondary to chronic PH, CDH neonates did 
not present differences when compared with control group. Moreover, PD-123319 
treatment did not change these parameters (Table 2). 
 Additionally, expression levels of right ventricular molecular markers of PH 
(Angiotensinogen, BNP and ET-1) were assessed in pups allowed to be delivered at 5 
minutes after birth. In Figure 7D, mRNA levels of these markers normalized to β-actin 
are shown. CDH+S group presented a significant increase of angiotensinogen and an 




















group. On its turn, PD-123319 treatment significantly decreased these overload markers 
on CDH pups. 
 
Antenatal PD-123319 treatment improves lung function and survival 
 The adaptation of fetuses to extra-uterine life was monitored within the first 5 
minutes after delivery by determining an APGAR-like score (0-8). CDH+S neonates 
presented an APGAR score of 2.35 ± 0.17, 1.82 ± 0.12 and 2.28 ± 0.18, at 1, 3 and 5 
minutes after birth, respectively. On the other hand, antenatal PD-123319 treatment 
improved APGAR score to 3.23 ± 0.26, 2.97 ± 0.09 and 2.71 ± 0.13, at 1, 3 and 5 
minutes after birth (p<0.05), respectively. 
 Five minutes after birth, a moment in which all neonates were alive, neonates of 
C+S, N+S, CDH+S, N+PD and CDH+PD groups were used for blood collection 
(collected after decapitation) and gasometric evaluation. When compared with control 
pups, neonates of nitrofen treated dams (N+S and CDH+S) presented significant 
acidosis, decrease of PO2 and SatO2, and increase of PCO2 and lactate, which was 
maximal in CDH+S neonates (pups with maximal degree of lung hypoplasia)  (Table 3). 
On its turn, antenatal PD-123319 treatment allowed a statistical significant increase of 
pH, PO2 and SatO2, and decrease of PCO2 and lactate concentration. Indeed, there was 
no difference in gasometric parameters between control, nitrofen and CDH groups 
treated with PD-123319 (Table 3).  
 Concerning neonatal survival, the average survival time was significantly longer 
in PD-123319 treated pups than in CDH+S pups (30.3 ± 3.2 minutes for CDH+S versus 
42.4 ± 1.3 minutes for CDH+PD, p<0.001). As a result, all CDH+PD pups, but only 
57% of the CDH+S pups, survived for up to 30 minutes. At 45 minutes after birth, only 




















PD-123319 treatment increased survival rates of CDH neonates for all time points 
evaluated (Figure 8). 
 Regarding potential secondary effects of PD-123319 on maternal organs, their 
lungs, heart and kidneys were weighed. PD-123319 treatment did not significantly 





















This study demonstrated that all components of RAS (renin, ACE, 
angiotensinogen, AT1 and AT2 receptors) were constitutively expressed in the lung 
during all studied gestational ages and that ANGII had a stimulatory effect on lung 
branching, mediated by AT1 receptor, through p44/42 and Akt phosphorylation. This 
stimulatory effect on lung growth was mimicked by treatment with AT2-antagonist. 
Therefore, AT2 receptor antagonist was evaluated as a putative antenatal treatment for 
diseases characterized by fetal lung hypoplasia such as CDH. In an animal model of 
CDH, antenatal PD-123319 treatment increased neonatal lung growth, ameliorated 
indirect parameters of PH, improved lung function and survival, without maternal or 
fetal deleterious effects. 
 In last years, it has been demonstrated that local ANGII formation and its tissue-
specific effects on growth and differentiation are thought to be extremely important for 
embryonic and fetal development (12). Regarding fetal lung, this study corroborated 
previous evidences concerning ACE, AT1 and AT2 expression (13-15, 25). For the first 
time, the present study showed that renin and angiotensinogen are also expressed during 
lung development. Interestingly, renin, ACE and AT2 were expressed at very early 
stages (since 13.5 dpc), suggesting an important role for a local RAS since early stages 
of lung development. 
 The results of RAS components expression prompted us to hypothesize that a 
local RAS is active in the developing lung. Therefore, the role of ANGII on lung 
morphogenesis was evaluated. ANGII supplementation induced an increase in lung 
explants growth, and it is necessary to stress that this enhancing effect of ANGII on 
number of peripheral airways buds of lung reached about 37%, whereas the stimulatory 




















lung growth factor, in a similar model of murine lung explants, was around 20% (26). 
The possible mechanism by which RAS interferes with the airway branching or 
pulmonary vascular development is still unclear and further investigation is required. 
However, it was already substantially demonstrated that reciprocal interactions between 
airways and blood vessels are critical for normal lung development. For instance, it was 
demonstrated that ablation of lung epithelium impair lung vascular cells development 
(27). Moreover, VEGF inhibition in neonatal rats leads to arrested alveolar 
development, suggesting that inhibition of vascular growth itself may directly impair 
lung development (28-30). Thus, given that in the present study it was demonstrated 
that some components of RAS are expressed on epithelium and others on 
mesenchyme/vascular cells, it is possible that RAS is involved in both processes: airway 
and vasculature branching.  
  Interestingly, AT1 receptor inhibitor decreased, whereas AT2-antagonist 
significantly increased lung growth in explants. This opposite effect of AT1 and AT2 
receptors, namely a stimulatory effect of AT1 and inhibitory effect of AT2, is also 
described on other tissues (31-36). 
 Many of the effectors that modulate fetal lung branching seem to activate 
MAPK and/or PI3K/Akt cascades (37). Thus, MAPK and PI3K/Akt pathway activation 
by ANGII and AT1 and AT2 antagonists in fetal lung development was investigated. 
ANGII and AT2 receptor antagonist treatment induced an increase in lung branching by 
the stimulation of p44/42 and Akt phosphorylation. These intracellular mediators are 
also involved in AT1 effects on proliferation and survival of cells in other tissues (31, 
33). Regarding lung growth inhibition induced by AT1 antagonist, it was mediated by a 
decrease of p-38 and JNK phosphorylation. These MAPK families were already 




















 The in vitro studies demonstrated that a local RAS is functional at early stages of 
lung morphogenesis. Moreover, the significant stimulatory effect on lung growth 
mediated by AT2 receptor antagonist led us to hypothesize that AT2 could be a new 
target for treatment of diseases characterized by fetal lung hypoplasia, such as CDH. In 
fact, AT2 receptor is described to be expressed virtually only during fetal life (11, 12, 
38), which would annul potential maternal adverse effects. Thus, treatment with AT2 
antagonist (PD-123319) was selected for the in vivo study, in which the nitrofen-
induced CDH rat model (16, 39) was used. The gestational age selected for maternal 
PD-123319 administration was based on the effect observed on lung explants that were 
harvested at 13.5 dpc. The nitrofen-induced CDH model is an experimental model of 
severe lung hypoplasia, which reasonably replicates the major abnormalities and the 
pathophysiology described in human CDH (39-41). Although the mechanism by which 
nitrofen induces the diaphragmatic defect and lung hypoplasia is not fully understood, 
recent evidences suggest the involvement of abnormalities linked with the retinoid 
signaling pathway in this model and also in human CDH etiology (39-42). Indeed, one 
clinical study demonstrated the presence of decreased levels of retinol and retinol-
binding protein in human CDH, suggesting a possible deterioration of retinol transport 
across the placenta (43). Regarding the nitrofen-induced CDH model, it was already 
demonstrated that nitrofen inhibits retinal dehydrogenase 2 (RALDH2), a key enzyme 
responsible for the conversion of retinal to retinoic acid (44). Moreover, the co-
administration of retinoids (Vitamin A or retinoic acid) in nitrofen-induced CDH 
induces lung growth and reduces the incidence of CDH (9, 10, 45). Interestingly, some 
studies have described an inhibitory interaction between retinoid acid pathway and 




















retinoid acid pathway and RAS might be present during lung morphogenesis, but the 
underlying mechanisms remain unclear and further investigation is required.  
 Maternal PD-123319 subcutaneous administration significantly increased lung 
growth in control, nitrofen and CDH groups. In fact, in CDH neonates, despite the 
presence of mechanical forces that compress lungs, PD-123319 induced partial recovery 
of lung hypoplasia as assessed by LW/BW (an increase of 11.4%). In face of these 
results and in order to assess if the treated-lung is structural and functionally 
ameliorated, we focused further studies in comparing C+S, CDH+S and CDH+PD 
groups. In human and experimental CDH there is a reduction in peripheral lung 
development (1, 10). PD-123319 treatment stimulated lung growth by promoting distal 
lung development as measured by the enhanced RSC. The potential clinical relevance of 
this effect should be emphasized, since such an increase in lung parenchyma can be 
determinant in providing a better adaptation of CDH fetus to extra-uterine life. 
 Regarding epithelial differentiation and lung maturity, CCSP (a Clara cells 
marker, marker for proximal lung), SP-C (a type II pneumocytes marker, marker for 
distal lung) and PAS glycogen stores (a signal of immaturity) were assessed. No 
differences between groups were detected in CCSP, SP-C and PAS-stained cells score. 
Contradictory results about lung maturity and surfactant status in CDH animal models 
have been published, with studies demonstrating that the CDH lung is surfactant 
deficient (48-50) and others indicating no change in alveolar surfactant composition, 
unchanged or even increased surfactant protein expression (51-54). However, one of the 
most recent studies performed with human CDH fetuses demonstrated that surfactant 
maturation is not delayed (51). The present study corroborates the idea that CDH does 




















(51). Moreover, PD-123319 treatment did not impair fetal lung maturation in CDH 
neonates.  
 Persistent PH accounts for significant mortality and morbidity in CDH (1, 2, 55). 
In severe human CDH and also in nitrofen-induced model of CDH, it was already 
demonstrated that PH results from decreased number of arteries, increased thickness of 
media and adventitia of pulmonary arterial walls and distal muscular extension to the 
non-muscular intra-acinar arteries (55, 56). In this study, the effect of PD-123319 
treatment on PH was indirectly assessed by morphometric pulmonary vascular analysis 
(56) and its cardiac repercussion by determination of right ventricular hypertrophy 
index and right ventricle thickness, and quantification of right ventricular overload 
molecular markers (Angiotensinogen, BNP and ET-1) (24). To better analyze the vessel 
morphology, areas were measured instead of thickness since this approach avoids the 
bias introduced by irregular shape of elastic laminae. Thus, PD-123319 treatment 
induced decrease of MA percentage for all arterial sizes, with maximal effect on smaller 
arteries. Moreover, CDH+S neonates did not present differences in right ventricular 
hypertrophy index and right ventricular wall thickness (morphological markers) when 
compared with C+S group, but they presented an increase of molecular markers of right 
ventricular overload. Thus, 5 minutes after birth, CDH+S neonates only presented 
molecular changes secondary to PH, but not yet morphological alterations (secondary to 
chronic PH). PD-123319 treated CDH pups presented a significantly decrease of right 
ventricular overload molecular markers and did not influence morphological markers. 
Therefore, PD-123319 maternal administration partially reversed pulmonary arterial 
structural abnormality that characterizes CDH and decreased molecular markers of PH, 
which suggest that PD-123319 might reduce pulmonary vascular reactivity, and the risk 




















 Regarding other antenatal pharmacological strategies to decrease PH in CDH, 
Luong et al demonstrated recently that antenatal sildenafil treatment (from 11.5 to 20.5 
dpc, daily subcutaneous injection) attenuates PH in experimental CDH. In fact, that 
study demonstrated that antenatal sildenafil treatment improved lung structure, 
increased pulmonary vessel density and reduced right ventricular hypertrophy in CDH 
(3). However, in opposition to PD-123319 treatment, sildenafil had not promoted lung 
growth, as demonstrated by LW/BW, and consequently it did not induce a recover of 
lung hypoplasia (3). Moreover, it is necessary to stress that the idea that there is PH in 
CDH, since fetal period, is underlying to Luong’s study (3). Nonetheless, it was already 
demonstrated that there is vascular hypoplasia in nitrofen-induced CDH and neonatal 
PH, but it is not yet proven the presence of PH in CDH fetus (24, 55, 56). Indeed, 
immediately after the birth, Luong et al demonstrated the presence of right ventricular 
hypertrophy (an indirect signal of PH) in CDH neonates (3). In the present study, CDH 
neonates at 5 minutes after the birth did not present increase of right ventricular 
hypertrophy index or right ventricle thickness. However, CDH+S neonates presented an 
increase of right ventricular overload markers which reveals a molecular cardiac 
repercussion. According to the literature, it was already demonstrated that CDH 
vascular pulmonary alterations only affect neonatal and not fetal hemodynamics. 
Baptista et al demonstrated that CDH is associated with significant molecular 
alterations secondary to PH, but only in the right ventricle and after birth (24). 
Moreover, also in fetal lamb CDH model, it was demonstrated that newborn CDH 
lambs had no differences in right ventricular weight or right ventricular wall thicknesses 
compared to control lambs (57). Thus, despite the occurrence of pulmonary vascular 
modifications from early stages of prenatal development, the present study also shows 




















that characterizes CDH, and also consequently to pulmonary vasoconstriction, which is 
secondary to alveolar hypoplasia, hypoxia and acidosis. 
So, antenatal PD-123319 treatment interfered and improved the key determinants of 
mortality associated with CDH, namely lung hypoplasia and PH. Furthermore, maternal 
PD-123319 administration improved lung function, namely pulmonary gas exchange, as 
demonstrated by APGAR score, gasometric and survival evaluation. Regarding 
gasometry it is necessary to stress that due to low fetal blood volume, all blood possibly 
collected by decapitation was used for gasometric evaluation. So, gasometry evaluated a 
mix of arterial and venous blood. Nonetheless, antenatal PD-123319 treatment allowed 
a statistical significant improvement of acidosis, hypercapnia, hypoxia and lactate 
concentration that characterizes CDH fetuses. The results of these direct indicators of 
ventilation/perfusion matching quality suggest an obvious improve of pulmonary gas 
exchange and peripheral O2 delivery. Furthermore, this enhancement on lung function 
had important consequences on neonatal survival, namely PD-123319 treatment 
induced significantly longer average survival time. However, it is necessary to stress 
that the survival evaluation was performed without neonatal care or ventilatory support. 
This fact might be the explanation for the death of all neonates, despite the increase on 
lung function and survival time induced by antenatal PD-123319 treatment. 
 Regarding potential fetal adverse effects, the nitrofen-exposed pups presented 
decrease of HW/BW and KW/BW ratios as previously documented (10, 58-60). On the 
other hand, PD-123319 beneficial effect seemed lung-specific, since HW/BW and 
KW/BW ratios of the pups were not altered. Concerning potential maternal secondary 
effects induced by PD-123319, no differences on heart, kidneys and lungs were 
observed. The absence of maternal deleterious effects could be due to the fact of AT2 




















organs (11, 12, 38). Indeed, an increase of AT2 receptor expression during adult life has 
been only observed under pathological conditions (38). 
 In conclusion, this study demonstrated the existence of a functional local RAS in 
fetal lung. Moreover, it establishes AT2 receptor antagonist (PD-123319) as a putative 
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Figure 1. Protein expression pattern of RAS components during fetal lung development 
(from 15.5 until 21.5 dpc). (A) Renin was predominantly expressed in epithelium. (B) 
ACE expression. (C) Angiotensinogen expression in epithelial, endothelial (arrow) and 
vascular smooth muscle cells (arrowhead). (D) AT1 receptor immunostaining. (E) AT2 
receptor immunostaining. Original magnification x200. 
 
Figure 2. Branching morphogenesis in a rat lung explant system. (A) Representative 
examples of control and fetal lung explants treated with ANGII at 10-9 M, ZD-7155 (an 
AT1-antagonist) or PD-123319 (an AT2-antagonist). Original magnification x25. (B) 
Number of total airway buds of lung explants treated with increasing ANGII 
concentrations or (C) with ZD-7155 (ZD), PD-123319 (PD), ANG 10-9 + ZD or ANG 
10-9 + PD. Results are expressed as ratio of day 4 (D4) and day 0 (D0) of culture (D4/D0 
ratio). p<0.05: * vs. ANGII at 0 M (control, C), § vs. ANGII at 10-9 M, † vs. ZD-7155 at 
10-5 M, ‡ vs. ANG 10-9 + ZD. 
 
Figure 3. MAPK and Akt kinase activities in control (C) lung explants and treated with 
ANGII at 10-9 M (Ang 10-9), ZD-7155 (ZD) or PD-123319 (PD). (A) Western blot 
analysis of p38, p44/42, JNK1/2, and Akt and to diphosphorylated forms of p38 (dp-
p38), p44/42 (dp-p44/42), SAPK/JNK (dp-JNK1/2) and Akt (dp-Akt). Control loading 
was performed using β-tubulin (55 kDa). p38 corresponds to 38 kDa. p44/42 correspond 
to 44 and 42 kDa, respectively. JNK1 and 2 correspond to 46 and 54 kDa, respectively. 
Akt corresponds to 56 kDa. Semi-quantitative analysis for dp-p38 (B), dp-p44/42 (C), 




















β-tubulin. p<0.05: * vs. ANGII at 0 M (control, C), § vs. ANGII at 10-9 M, † vs. ZD-7155 
at 10-5 M. 
 
Figure 4. In vivo antenatal PD-123319 treatment effects on lung growth. (A) Ratio of 
left, right and total lung-to-body weight in control (C), nitrofen (N) and CDH groups 
treated with saline (C+S, N+S, CDH+S) or PD-123319 (C+PD, N+PD, CDH+PD). 
Antenatal administration of PD-123319 enhanced lung growth in all studied groups. (B) 
Effect of PD-123319 treatment on left, right and total lung hypoplasia. Prenatal 
administration of PD-123319 ameliorated both left and right lung hypoplasia. Results 
are expressed as %. p<0.001: * vs. C+S, † vs. N+S, ‡ vs. CDH+S, ll vs. C+PD, § vs. 
N+PD. For left lung there is a statistically significant interaction between variables: 
disease*treatment (p=0.009). 
 
Figure 5. Antenatal PD-123319 treatment increased RSC.. (A) Representative H&E 
stained sections of C+S, CDH+S and CDH+PD lungs, used to RSC analyzes. Note 
greater saccular development and increase of lung aeration in CDH+PD compared with 
CDH+S. Original magnification x100. (B) Mean radial saccular count in C+S, CDH+S 
and CDH+PD groups. PD-123319 treatment induced increase of RSC in CDH pups. 
p<0.001: * vs. C+S, ‡ vs. CDH+S. 
 
Figure 6. Antenatal PD-123319 treatment did not interfere with epithelial 
differentiation and lung maturation. (A) Representative CCSP stained sections of C+S, 
CDH+S and CDH+PD lungs. Original magnification x100. (B) Score of CCSP-stained 
cells in C+S, CDH+S and CDH+PD groups. (C) Representative SP-C stained sections 




















Representative PAS stained sections of C+S, CDH+S and CDH+PD lungs. Original 
magnification x400. Arrows: PAS+ (glycogen-rich) cells. (F) Score of PAS-stained 
cells. No significant difference between experimental groups was observed in CCSP, 
SP-C and PAS. 
 
Figure 7. Indirect pulmonary hypertension assessment. (A) In upper panel are presented 
representative examples of pulmonary arteries >50 μm stained with Weigert’s resorcin 
fuchsin solution of C+S, CDH+S and CDH+PD groups); in lower panel, representative 
examples of small pulmonary vessels (<30 μm) for each group are presented. Original 
magnification x400. (B) Percent medial area of pulmonary arteries of different external 
diameters. (C) Percent adventitial area of pulmonary arteries of different external 
diameters. (D) Right ventricular levels of angiotensinogen, BNP and ET-1 mRNA in 
C+S, CDH+S and CDH+PD neonates, expressed in arbitrary units normalized for β-
actin. PD-123319 treatment significantly decreased arterial medial area and these 
overload markers on CDH pups. p<0.001: * vs. C+S, ‡ vs. CDH+S. 
 
Figure 8. Survival analysis. (A) Representative examples of cyanotic color of CDH+S 
versus pink coloration of CDH+PD neonates at 5 minutes of life. (B) Survival rates 
(expressed as percentage of pups surviving at each 5 minutes) of CDH+S and CDH+PD 
neonates. Antenatal PD-123319 treatment improved survival time in CDH pups (mean 




















Table 1. APGAR-like score. This score is obtained by assigning a value (0, 1 or 2) to 4 
characteristics: skin color, breathing, spontaneous motor activity and reactivity to 
stimulus. The score vary between 0 and 8. 
 
Sign Score 0 Score 1 Score 2 
Skin color Marked cyanosis Mild cyanosis/ pale Pink 
Breathing Apnea 





No movements Weak movements Vigorous movements 























Table 2. Right ventricular hypertrophy evaluation 5 minutes after birth. 
 
 
Ratio of right/left 
ventricular weight 
Right ventricular wall 
thickness (μm) 
C+S 0.49±0.08 214.02±9.29 
CDH+S 0.44±0.05 200.59±4.27 
CDH+PD 0.52±0.05 220.31±12.26 
C: control; CDH: congenital diaphragmatic hernia; PD: PD-123319; S: Saline; 
Values represent the mean ± SEM of measurements. p<0.05: No significant 



















Table 3. Neonatal blood gasometric evaluation 5 minutes after birth. 
      
      
      
      
 pH PCO2 (mmHg) PO2 (mmHg) SatO2 (%) Lactate (mmol/L) 
C+S 7.30±0.03 22.69±2.33 102.80±7.78 93.60±2.50 6.83±0.39 
N+S 6.94±0.03* 38.49±3.21* 62.50±5.36* 67.25±5.58* 8.50±0.51* 
CDH+S 6.92±0.02* 51.05±1.71*† 52.00±6.06* 58.50±7.06* 9.56±0.57* 
N+PD 7.18±0.08† 23.62±3.39† 95.67±6.49† 90.83±2.44† 6.88±0.82† 
CDH+PD 7.03±0.04‡§ 24.63±5.83‡ 95.00±8.20‡ 87.80±3.65‡ 6.73±0.70‡ 
C: control; CDH: congenital diaphragmatic hernia; N: nitrofen; PD: PD-123319; PCO2: CO2 partial pressure; PO2: O2 partial pressure; S: Saline; SatO2: O2 saturation. Values 
represent the mean ±SEM of measurements. p<0.05: * vs. C+S, † vs. N+S, ‡ vs. CDH+S, § vs. N+PD. There is a statistically significant interaction between variables: 
disease*treatment for pH, PCO2, PO2 and SatO2. 
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Supplemental Figure 1. Protein expression pattern of renin-angiotensin system 
components during early stages of fetal lung development. (A-D) Renin expression at 
13.5, 15.5, 17.5 and 19.5 days post-conception (dpc), respectively. Renin protein 
expression appears to be maximal in the branching buds. (E) ACE and (F) AT2 receptor 
expression in epithelial cells at 13.5 dpc. Original magnification: x100 (B-D), x200 (A), 
x400 (E, F). 
 
Supplemental Figure 2. Antenatal PD-123319 treatment effects on fetal heart and 
kidney. Heart-to-body weight and kidney-to-body weight ratios in control (C), nitrofen 
(N) and CDH groups treated with saline (C+S, N+S, CDH+S) or PD-123319 (C+PD, 
N+PD, CDH+PD). The nitrofen treatment (nitrofen and CDH groups) induced decrease 
of heart and kidney-to-body weight ratios. Antenatal PD-123319 administration did not 
significantly change either heart or kidney growth. Results are expressed as %. p<0.05: 
* vs. C+S, ll vs. C+PD. 
 
Supplemental Figure 3. Heart, kidney and lung-to-body weight ratios in control and 
exposed to nitrofen pregnant rats, treated with (C+S, N+S) or PD-123319 (C+PD, 
N+PD). PD-123319 treatment did not significantly change heart, kidney or lung-to- 






















per animal (n) 
ED (μm) ID (μm) MA(%) AA (%) 
C+S 71.33±11.62 49.86±1.65 44.43±1.63 23.71±0.62 16.04±0.41 
CDH+S 62.2±12.99 35.01±1.51* 27.75±1.49* 43.67±1.27* 30.27±0.87* 
CDH+PD 70.33±9.60 34.69±1.34* 29.96±1.33*‡ 30.07±0.84*‡ 29.14±0.79* 
AA: adventitial area; C: control; CDH: congenital diaphragmatic hernia; ED: external diameter; ID: internal diameter; MA: medial area; PD: PD-123319; S: saline. Values 
represent the mean ±SEM of measurements. p<0.001: *vs. C+S; ‡vs. CDH+S. 
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